Medical Device Bio-engineered Stent Market Trends And Growth | Page 3

REPORT DESCRIPTION
Bio-engineered Stent Market – Dynamics
Increasing prevalence of renal diseases is a major factor driving bio-engineered stents market growth.
According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause
of death worldwide, accounting for over 17.9 million deaths annually and this number is expected to
increase to over 23.6 million by 2030. According to the same source, cardiovascular diseases accounted for
around 836,546 deaths in the U.S. in 2015, which accounted for around 1 in every 3 deaths.
Moreover, key players in the market are focused on adopting various strategies such as new Product Type
launch and approvals and partnerships and collaborations to increase their foothold in the market. For
instance, in May 2017, Medtronic plc., received the U.S. Food and Drug Administration (FDA) approval
and Resolute Onyx, 4.5 MM and 5 mm sizes Drug-Eluting Stent. This device has proven clinical
performance and superior deliverability of the Resolute Integrity. This device is intended to treat people
with coronary artery disease in the U.S.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2484